1-11 of 11
Anesh Panchal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Clinical Trials & Observations
John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D’Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (8): 839–850.
https://doi.org/10.1182/blood.2021015014
Published: 2022
Includes: Supplemental data
Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2021) 138 (Supplement 1): 525.
https://doi.org/10.1182/blood-2021-148359
Published: 2021
Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings
Journal: Blood
Blood (2021) 138 (Supplement 1): 2479.
https://doi.org/10.1182/blood-2021-147780
Published: 2021
Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Franck Morschhauser, Carmelo Carlo-Stella, Michael Dickinson, Tycel Phillips, Roch Houot, Fritz Offner, Corinne Haioun, Paolo Corradini, Martin Hutchings, Anna Sureda, Joaquín Martínez-López, Tomasz Wrobel, Shang-Ju Wu, Linda Lundberg, Estefania Mulvihill, David Perez-Callejo, James Relf, Anesh Panchal, Kathryn Humphrey, Emmanuel Bachy
Journal: Blood
Blood (2021) 138 (Supplement 1): 128.
https://doi.org/10.1182/blood-2021-148778
Published: 2021
Journal Articles

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead
Journal: Blood
Blood (2019) 134 (23): 2107–2111.
https://doi.org/10.1182/blood.2019001861
Published: 2019
Includes: Supplemental data
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt
Journal: Blood
Blood (2019) 134 (Supplement_1): 2871.
https://doi.org/10.1182/blood-2019-123978
Published: 2019
Journal Articles

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Jennifer O'Sullivan, MB BCh BAO, Angela Hamblin, MD PhD, Anesh Panchal, BSc, MSc, Christina Yap, MSci, PhD CStat, Sonia Fox, BSc, Samah Alimam, DHSC, MD, Helene Marie-Pierre Dreau, Kieran Howard, Pauline Ware, Samantha Baker, Nicholas C.P. Cross, Mary Frances McMullin, MD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1784.
https://doi.org/10.1182/blood-2018-99-118220
Published: 2018
Journal Articles

Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)

Mark Cook, MBChB,PhD, Anesh Panchal, BSc, MSc, Kristian Brock, MSc, BSc, Grant McQuaker, MD, John A. Snowden, MD, Charles R Crawley, Hannah Hunter, MB,FRCPath,MRCP, James D Cavenagh, Mirjana Sirovica, BSc(Hons), MSc, Andrea Hodgkinson, BSc(Hons),PhD, Gordon Cook, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 3308.
https://doi.org/10.1182/blood.V130.Suppl_1.3308.3308
Published: 2017
Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Toby A. Eyre, MBBChir, MRCP, Catherine Hildyard, MRCP, BA, Anesh Panchal, BSc, MSc, Aimee E Houlton, BSc, MSc, Louise Hopkins, BSc, MRes, Angela Hamblin, MD PhD, Kim Linton, MBChB PhD, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD, Kate Cwynarski, PhD MD, Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, David Wrench, MA, MBBChir, FRCPath, PhD, Andrew Davies, PhD, Graham Collins, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5210.
https://doi.org/10.1182/blood.V130.Suppl_1.5210.5210
Published: 2017
Journal Articles

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Clinical Trials & Observations
Claire N. Harrison, Adam J. Mead, Anesh Panchal, Sonia Fox, Christina Yap, Emmanouela Gbandi, Aimee Houlton, Samah Alimam, Joanne Ewing, Marion Wood, Frederick Chen, Jason Coppell, Nicki Panoskaltsis, Steven Knapper, Sahra Ali, Angela Hamblin, Robyn Scherber, Amylou C. Dueck, Nicholas C. P. Cross, Ruben Mesa, Mary Frances McMullin
Journal: Blood
Blood (2017) 130 (17): 1889–1897.
https://doi.org/10.1182/blood-2017-05-785790
Published: 2017
Includes: Supplemental data
Journal Articles

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Claire N. Harrison, DM, FRCP, FRCPath, Adam Mead, MD PhD, Sonia Fox, Anesh Panchal, BSc, MSc, Christina Yap, BSc, MSc, PhD, Aimee E Houlton, BSc, MSc, Samah Aliman, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Marion Wood, FRCP, FRCPath, Frederick Chen, MBBS, PhD FRCPath, Jason Coppell, Nicki Panoskaltsis, MD PhD, Steven Knapper, Sahra Ali, FRCPath, Angela Hamblin, MDPhD, Robyn M. Scherber, MD MPH, Holly Geyer, MD, Allison H Scotch, MD MPH, Amylou Constance Dueck, PhD, Nicholas CP Cross, PhD, Ruben A. Mesa, MD, Mary Frances McMullin, MD
Journal: Blood
Blood (2016) 128 (22): 1929.
https://doi.org/10.1182/blood.V128.22.1929.1929
Published: 2016